Month: September 2020

EJ FÖR DISTRIBUTION I ELLER TILL, ELLER TILL NÅGON PERSON SOM BEFINNER SIG I ELLER ÄR BOSATT I USA, DESS TERRITORIUM OCH BESITTNINGAR (INKLUSIVE PUERTO RICO, DE AMERIKANSKA JUNGFRUÖARNA, GUAM, AMERIKANSKA SAMOA, WAKEÖARNA, NORDMARIANERNA, VARJE DELSTAT I USA OCH DISTRICT OF COLUMBIA) ELLER TILL NÅGON AMERIKANSK PERSON (U.S. PERSON, SÅSOM DEFINIERATS I REGULATION S I UNITED STATES SECURITIES ACT OF 1933, I DESS NUVARANDE LYDELSE) ELLER NÅGON JURISDIKTION DÄR UTGIVANDE, PUBLICERING ELLER DISTRIBUTION AV DETTA DOKUMENT ÄR FÖRBJUDET ENLIGT LAG. DISTRIBUTION AV DETTA DOKUMENT KAN STRIDA MOT LAG I VISSA JURISDIKTIONER (I SYNNERHET USA OCH STORBRITANNIEN)Bilia AB (publ) (“Bolaget”) erbjuder innehavare av Bolagets utestående, nedan listade obligationer (”Obligationerna”) att delta i ett återköp där Bolaget köper tillbaka Obligationer mot kontant...

NANTES, France, Sept. 21, 2020 (GLOBE NEWSWIRE) — OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) presented positive results from Step-1 of its Phase 3 trial of neoepitope-based cancer vaccine Tedopi®, in patients with advanced non-small cell lung cancer (NSCLC) after failure of previous checkpoint inhibitor treatments, at the 2020 European Society for Medical Oncology (ESMO) Virtual Conference.Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics, said: “These are very exciting results for Tedopi® and the improvement in overall survival, which was substantially above the standard of care, demonstrates that our neoepitope cancer vaccine has the potential to make a truly important difference to the lives of advanced NSCLC patients. In addition, the significantly longer survival after progression, the sustained...

Press ReleaseNokia President and CEO, Pekka Lundmark signs a  joint Statement that will be handed to the UN Secretary General General to mark the 75th anniversary of the United NationsThe Statement commits more than 1,000 leaders to: ethical leadership and good governance; invest in addressing inequalities and injustice; promote equality and respect human rights          21 September 2020Espoo, Finland – Nokia President and CEO, Pekka Lundmark has signed a joint UN Statement, UNITED IN THE BUSINESS OF A BETTER WORLD which will be presented to the UN Secretary General as part of celebration of the 75th anniversary of the United Nations.The Statement, signed by more than 1,000 global CEOs, says that at time of unprecedented disruption and global transformation, international cooperation must be mobilized across borders, sectors and generations. ...

Paris, le 21 septembre 2020 à 7h00ILIAD ANNONCE SON INTENTION D’ACQUÉRIR L’OPÉRATEUR POLONAIS PLAYLancement d’une offre publique sur Play, leader du marché mobile polonais avec 15 millions d’abonnés et sécurisation d’un bloc de contrôle de 40% auprès des deux actionnaires de référence. Iliad et Play partagent une histoire de réussite semblable comme derniers entrants mobile dans trois grands pays européens. Réunis, ils représentent 41 millions d’abonnés en France, en Pologne et en Italie. Iliad sera le meilleur partenaire industriel pour accompagner la croissance de Play sur le marché mobile et optimiser son entrée sur le marché fixe. Un rapprochement dans l’intérêt des actionnaires d’iliad : une opportunité unique d’entrer sur un grand marché en croissance tout en générant un impact relutif sur le BPA et le FCF par action du groupe dès...

VANCOUVER, Washington, Sept. 20, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer and Scott A. Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, of CytoDyn will be interviewed on the DrBeen webcast hosted by Mobeen Syed, M.D., M.S. on Tuesday, September 22, 2020 at 6:00 pm PT.Topics to be covered:1) CD10: Mild-to-moderate COVID-19 results (U.K., U.S., Philippines, Canada)2) CD12: Upcoming interim analysis3) COVID-19: Upcoming trial in “long-haulers”4) COVID-19: Phase 3 trial in Moderate5) HIV BLA submission to U.K. and U.S.6) Leronlimab for stroke...

NASHUA, N.H., Sept. 20, 2020 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, is providing additional comments following the Centers for Medicare & Medicaid Services’ (CMS) publication of a new Innovation Center model designed, according to CMS, to improve the quality of care for cancer patients receiving radiotherapy and reduce Medicare expenditures through bundled payments. CMS indicated that the new Radiation Oncology (RO) Model allows this focus on value-based care by creating simpler, more predictable payments that incentivize cost-efficient and clinically effective treatments to improve quality and outcomes. The RO Model, part of a final rule on specialty care models issued by CMS, is scheduled to be implemented on January 1,...

Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%In the overall trial population, Libtayo reduced risk of death by 32% compared to chemotherapyIn a prespecified analysis of patients with confirmed PD-L1 expression of ≥50%, Libtayo reduced risk of death by 43%PARIS and TARRYTOWN, N.Y. – September 21, 2020 – Positive pivotal trial data for the investigational use of PD-1 inhibitor Libtayo® (cemiplimab) in first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) were shared in a presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.The trial compared Libtayo monotherapy to platinum-doublet chemotherapy in patients whose tumor cells expressed PD-L1, including...

Une présentation de dernière minute au congrès de l’ESMO montre qu’une monothérapie par Libtayo® (cemiplimab) augmente la survie globale des patients atteints d’un cancer du poumon non à petites cellules dont 50 % ou plus des cellules tumorales expriment la protéine PD-L1Dans la population générale de l’essai, Libtayo a réduit le risque de décès de 32 %, comparativement à la chimiothérapie.Une analyse préspécifiée des données des patients dont 50 % ou plus des cellules tumorales exprimaient la protéine PD-L1 a montré que Libtayo a réduit le risque de décès de 43 %.PARIS et TARRYTOWN (NEW YORK) – Le 21 septembre 2020 – Les données positives d’un essai pivot consacré à l’inhibiteur de PD-1 expérimental Libtayo® (cemiplimab) dans le traitement de première ligne du cancer du poumon non à petites cellules (CPNPC) localement avancé ou métastatique...

MGD019 well-tolerated with early signals of activity in advanced solid tumors not typically responsive to checkpoint inhibitionRecommended Phase 2 dose established for MSS CRC, NSCLC expansion cohortsPresentation is available on-demand as part of the ESMO Virtual Congress 2020 ROCKVILLE, MD, Sept. 20, 2020 (GLOBE NEWSWIRE) —MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced clinical data from the dose escalation portion of a Phase 1 clinical trial of MGD019. The proffered paper session titled, “A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD019, an Investigational Bispecific PD-1 × CTLA-4 DART® Molecule in Patients with Advanced Solid Tumors,” was presented...

― Phase III SANET-p demonstrated surufatinib reduces the risk of disease progression or death by 51% in patients with pancreatic neuroendocrine tumors (“NET”) ―― SANET-p results complement previously presented positive Phase III SANET-ep results in patients with non-pancreatic NET, including across multiple subgroups ―― Results of both SANET-p and SANET-ep studies published in The Lancet Oncology –HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 20, 2020 (GLOBE NEWSWIRE) — Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that positive results of the Phase III study of surufatinib in advanced neuroendocrine tumors – pancreatic (“SANET-p”) were presented as a proffered paper session at the European Society for Medical Oncology (“ESMO”) Virtual Congress 2020 (Abstract Number 1156O). Results...